首页> Blood: The Journal of the American Society of Hematology> Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

导出原文传递

翻译打印收藏纠错

作者： Fink, Anna Maria ; Bahlo, Jasmin ; Sandra, Robrecht ; Al-Sawaf, Othman ; Aldaoud, Ali ; Hebart, Holger ; Jentsch-Ulrich, Kathleen ; Doerfel, Steffen ; Fischer, Kirsten ; Wendtner, Clemens Martin ; Noesslinger, Thomas ; Ghia, Paolo ; Bosch, Francesc ; Kater, Arnon P. ; Kreuzer, Karl-Anton ; Dohner, Hartmut ; Kneba, Michael ; Stilgenbauer, Stephan ; Boettcher, Sebastian ; Eichhorst, Barbara ; Hallek, Michael

发布时间 2020-08-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Blood

2016年128卷22期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

Blood

相似文献

Blood

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

Blood

相似文献

Blood

相关期刊

检索历史清除